AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03861650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
Study NCT03861650 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Physiological saline is added in control group to act as placebo
Study NCT06383065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT Group
Description: Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
Study NCT03326739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Line Placement
Description: arterial line placement
Study NCT04188470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: person-centered care model
Description: A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
Study NCT03239184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
Study NCT03239184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
Study NCT03239184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03239184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT01747226 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride rinse
Description: rinse with 15 ml for 1 minute
Study NCT01747226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Halita
Description: rinsing with 15 ml for 1 minute
Study NCT01747226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meridol Halitosis
Description: rinsing with 15 ml for 1 minute
Study NCT01747226 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: rinsing with 15ml for 1 minute
Study NCT00431678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
Study NCT00431678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin + Ceftriaxone
Description: Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
Study NCT03130608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
Study NCT03686514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLUARIX QUADRIVALENT
Description: The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
Study NCT01641874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Directional specific exercise
Study NCT02409784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-KD
Description: Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
Study NCT02409784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-KD
Description: After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
Study NCT01641874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evidence based exercise
Description: Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
Study NCT04242173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
Study NCT01904058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001
Study NCT01904058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01904058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Study NCT01904058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid
Study NCT03959072 — intervention group
Intervention type: DEVICE
Intervention: Robotic CTO PCI
Description: Randomized to robotic CTO PCI.
Study NCT03959072 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional (Manual) CTO PCI
Description: Randomized to manual CTO PCI.
Study NCT01435070 — intervention group
Intervention type: PROCEDURE
Intervention: Kirschner wire fixation
Description: The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment.
Study NCT01435070 — intervention group
Intervention type: PROCEDURE
Intervention: Volar Locking Plate fixation
Description: The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
Study NCT03428607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 160mg QD
Study NCT01408680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
Study NCT01408680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
Study NCT01408680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
Study NCT00751790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin embonate (INN)
Description: Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
Study NCT01253824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-01
Description: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
Study NCT01253824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IKH-01
Description: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
Study NCT00151996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate + SPD503 (Guanfacine hydrochloride)
Study NCT00151996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine + SPD503
Study NCT02074956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
Study NCT02074956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
Study NCT01673724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole
Description: pramipexole
Study NCT01673724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: bromocriptine
Study NCT04125797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of adhesive
Description: Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
Study NCT02688842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin target-eluting coronary stent systems (38mm)
Study NCT01515176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV
Study NCT01515176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01515176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT01515176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02000986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
Description: Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
Study NCT03901287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual energy CT scans
Description: The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
Study NCT02191085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track
Description: In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP.
Study NCT01860053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
Study NCT03428607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg BID
Study NCT02998892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise Training
Description: Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.
Study NCT02998892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Microbursts of Activity
Description: Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
Study NCT04070378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
Study NCT01806870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc and SAMe
Description: If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
Study NCT04215081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training using ExoAtlet exoskeleton
Description: Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
Study NCT00661752 — intervention group
Intervention type: DEVICE
Intervention: quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac
Description: Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
Study NCT02361957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02460835 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiation Therapy
Study NCT02274558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: NBI-98854 40 mg capsules
Study NCT02274558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NBI-98854 placebo capsules
Study NCT02320617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Magnetic Resonance Imaging
Description: Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
Study NCT01404962 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haemophilus influenza type b conjugate vaccine
Description: Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
Study NCT03389763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a rate of infusion will be increased by 50% every 5 minutes
Study NCT00099580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2592
Description: continuous subcutaneous infusion (via pump), dose based on subject body weight
Study NCT00099580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: continuous subcutaneous infusion (via pump), dose based on subject body weight
Study NCT00950716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Peer Support and Empowerment
Description: 30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
Study NCT00950716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
Study NCT04356807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reflex Locomotion Therapy
Description: The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.
Study NCT04356807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Joint Mobilizations
Description: Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008
Study NCT04356807 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: Soft massage with soft pressures in limbs, tactile stimulation and no motion.
Study NCT01117987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
Study NCT01117987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
Study NCT02721368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuramis® Volume Lidocaine
Description: hyaluronic acid filler
Study NCT02721368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm® Voluma® with Lidocaine
Description: hyaluronic acid filler
Study NCT03316040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JIC
Description: The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older.
Study NCT02248116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine
Study NCT01041209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy based on BPS guided antibiotic use
Description: In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
Study NCT01041209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enforced Guidelines
Description: In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
Study NCT04319458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fotonovela
Description: Secret Feelings/Sentimientos Secretos
Study NCT04319458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: NIH Brochure: Depression: What You Need to Know
Study NCT00756717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752
Description: Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
Study NCT03211455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: intravenous lidocaine versus placebo
Study NCT03211455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: intravenous isotonic saline
Study NCT01304186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Information
Description: The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.